4/28/2025

Janusmed kön och genus

Janusmed kön och genus – Metalyse

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Tenekteplas

Tenekteplas

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Metalyse 5000 IE (tenecteplase). Summary of Product Characteristics. European Medicines Agency (updated 2024-02-04, cited 2025-01-09]

  2. Metalyse 10 000 IE (tenecteplase). Summary of Product Characteristics. European Medicines Agency (updated 2024-02-04, cited 2025-01-09]

  3. Socialstyrelsen. Statistik om stroke 2023. Socialstyrelsen [www]. [updated 2024-11-19, cited 2025-01-09].

  4. Socialstyrelsen. Statistik om hjärtinfarkt 2023. Socialstyrelsen [www]. [updated 2024-11-26, cited 2025-01-27].

  5. Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.

  6. Kim DJ, Singh N, Catanese L, Yu AYX, Demchuk AM, Lloret-Villas MI et al. Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase. Stroke. 2024;55(2):288-295.

  7. Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781-788.

  8. Ihle-Hansen H, Sandset EC, Ihle-Hansen H, Hagberg G, Thommessen B, Rønning OM et al. Sex differences in the Norwegian Tenecteplase Trial (NOR-TEST). Eur J Neurol. 2022;29(2):609-614.

  9. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-22.

  10. Marnat G, Gerschenfeld G, Olindo S, Sibon I, Seners P, Clarençon F et al. Incidence and predictors of intracranial hemorrhage after intravenous thrombolysis with tenecteplase. Eur Stroke J. 2024;9(4):918-926.

  11. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22(24):2253-61.

  12. Lanaro E, Caixeta A, Soares JA, Alves CM, Barbosa AH, Souza JA et al. Influence of gender on the risk of death and adverse events in patients with acute myocardial infarction undergoing pharmacoinvasive strategy. J Thromb Thrombolysis. 2014;38(4):510-6.

  13. Sajobi TT, Arimoro OI, Ademola A, Singh N, Bala F, Almekhlafi MA et al. Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial. Stroke. 2024;55(3):524-531.

  1. Metalyse 5000 IE (tenecteplase). Summary of Product Characteristics. European Medicines Agency (updated 2024-02-04, cited 2025-01-09]
  2. Metalyse 10 000 IE (tenecteplase). Summary of Product Characteristics. European Medicines Agency (updated 2024-02-04, cited 2025-01-09]
  3. Socialstyrelsen. Statistik om stroke 2023. Socialstyrelsen [www]. [updated 2024-11-19, cited 2025-01-09].
  4. Socialstyrelsen. Statistik om hjärtinfarkt 2023. Socialstyrelsen [www]. [updated 2024-11-26, cited 2025-01-27].
  5. Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169.
  6. Kim DJ, Singh N, Catanese L, Yu AYX, Demchuk AM, Lloret-Villas MI et al. Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase. Stroke. 2024;55(2):288-295.
  7. Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781-788.
  8. Ihle-Hansen H, Sandset EC, Ihle-Hansen H, Hagberg G, Thommessen B, Rønning OM et al. Sex differences in the Norwegian Tenecteplase Trial (NOR-TEST). Eur J Neurol. 2022;29(2):609-614.
  9. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-22.
  10. Marnat G, Gerschenfeld G, Olindo S, Sibon I, Seners P, Clarençon F et al. Incidence and predictors of intracranial hemorrhage after intravenous thrombolysis with tenecteplase. Eur Stroke J. 2024;9(4):918-926.
  11. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22(24):2253-61.
  12. Lanaro E, Caixeta A, Soares JA, Alves CM, Barbosa AH, Souza JA et al. Influence of gender on the risk of death and adverse events in patients with acute myocardial infarction undergoing pharmacoinvasive strategy. J Thromb Thrombolysis. 2014;38(4):510-6.
  13. Sajobi TT, Arimoro OI, Ademola A, Singh N, Bala F, Almekhlafi MA et al. Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial. Stroke. 2024;55(3):524-531.